SI1635830T1 - Granulirana farmacevtska oblika rapamicin-estra cci-779 - Google Patents

Granulirana farmacevtska oblika rapamicin-estra cci-779

Info

Publication number: SI1635830T1
Authority: SI; Slovenia
Prior art keywords: granulate formulation; rapamycin ester; cci; ester cci; rapamycin
Prior art date: 2002-09-17

Application number

SI200331456T

Other languages

English (en)

Inventor

Muhammad Ashraf

Eric J Benjamin

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-17

Filing date

2003-09-15

Publication date

2009-02-28

2003-09-15 Application filed by Wyeth Corp filed Critical Wyeth Corp

2009-02-28 Publication of SI1635830T1 publication Critical patent/SI1635830T1/sl

Links

CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 title abstract 2
238000009472 formulation Methods 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 2
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 2
229960002930 sirolimus Drugs 0.000 title abstract 2
229960000235 temsirolimus Drugs 0.000 title abstract 2
150000002148 esters Chemical class 0.000 title 1
239000008187 granular material Substances 0.000 title 1
PTBDIHRZYDMNKB-UHFFFAOYSA-N 2,2-Bis(hydroxymethyl)propionic acid Chemical compound OCC(C)(CO)C(O)=O PTBDIHRZYDMNKB-UHFFFAOYSA-N 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Inorganic Chemistry (AREA)
Hematology (AREA)
Transplantation (AREA)
Oncology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Cosmetics (AREA)

SI200331456T 2002-09-17 2003-09-15 Granulirana farmacevtska oblika rapamicin-estra cci-779 SI1635830T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US41126402P	2002-09-17	2002-09-17
EP03754672A EP1635830B1 (en)	2002-09-17	2003-09-15	Granulate formulation of the rapamycin ester cci-779
PCT/US2003/029228 WO2004026280A2 (en)	2002-09-17	2003-09-15	Granulate formulation of the rapamycin ester cci-779

Publications (1)

Publication Number	Publication Date
SI1635830T1 true SI1635830T1 (sl)	2009-02-28

Family

ID=32030658

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200331456T SI1635830T1 (sl)	2002-09-17	2003-09-15	Granulirana farmacevtska oblika rapamicin-estra cci-779

Country Status (24)

Country	Link
US (1)	US20040077677A1 (sl)
EP (1)	EP1635830B1 (sl)
JP (1)	JP2006506353A (sl)
KR (1)	KR20050084559A (sl)
CN (1)	CN100415233C (sl)
AT (1)	ATE413163T1 (sl)
AU (1)	AU2003272489B2 (sl)
BR (1)	BR0314397A (sl)
CA (1)	CA2496332A1 (sl)
CR (1)	CR7791A (sl)
DE (1)	DE60324609D1 (sl)
DK (1)	DK1635830T3 (sl)
EC (1)	ECSP055731A (sl)
ES (1)	ES2315530T3 (sl)
IL (1)	IL166824A0 (sl)
MX (1)	MXPA05002828A (sl)
NO (1)	NO20050836L (sl)
NZ (1)	NZ538781A (sl)
PT (1)	PT1635830E (sl)
RU (1)	RU2326654C2 (sl)
SI (1)	SI1635830T1 (sl)
UA (1)	UA81265C2 (sl)
WO (1)	WO2004026280A2 (sl)
ZA (1)	ZA200502220B (sl)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101717410B (zh)	2002-02-01	2015-04-29	阿里亚德医药股份有限公司	含磷化合物及其应用
US7776314B2 (en)	2002-06-17	2010-08-17	Grunenthal Gmbh	Abuse-proofed dosage system
AR042938A1 (es) *	2003-02-06	2005-07-06	Wyeth Corp	Uso del cci-779 en el tratamiento de la fibrosis hepatica
MXPA05010582A (es) *	2003-04-22	2005-11-23	Wyeth Corp	Combinaciones antineoplasicas.
EP1648454A1 (en) *	2003-07-25	2006-04-26	Wyeth	Cci-779 lyophilized formulations
US20070048228A1 (en)	2003-08-06	2007-03-01	Elisabeth Arkenau-Maric	Abuse-proofed dosage form
DE102005005446A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de)	2003-08-06	2005-03-24	Grünenthal GmbH	Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de)	2003-12-24	2005-09-29	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
AU2004270154A1 (en)	2003-09-03	2005-03-17	Wyeth	Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
BRPI0418373A (pt) *	2004-01-08	2007-05-22	Wyeth Corp	composição farmacêutica, unidade de dosagem de cci-779 oral, método de fornecimento de cci-779 a um paciente, e, uso de cci-779 micronizado
US7349971B2 (en) *	2004-02-05	2008-03-25	Scenera Technologies, Llc	System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
MXPA06011883A (es)	2004-04-14	2006-12-14	Wyeth Corp	42-ester de prolina-rapamicina con acido 2,2-bis(hidroximetil)propionico y sintesis enzimatica de dos etapas de 42-ester de prolina-rapamicina con acido 2,2-bis(hidroximetil)propionico y 42-ester de rapamicina con acido 2,2-bis(hidroximetil)propionic
DE102004032049A1 (de)	2004-07-01	2006-01-19	Grünenthal GmbH	Gegen Missbrauch gesicherte, orale Darreichungsform
MX2007005153A (es)	2004-10-28	2007-06-26	Wyeth Corp	Uso de un inhibidor del mtor en el tratamiento de leiomioma del utero.
DE102005005449A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20060183766A1 (en) *	2005-02-15	2006-08-17	Wyeth	Orally bioavailable CCI-779 formulations
CN103110948A (zh)	2005-11-04	2013-05-22	惠氏公司	mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
US7538119B2 (en) *	2005-11-04	2009-05-26	Wyeth	41-Methoxy isotope labeled rapamycin 42-ester
CN101360495B (zh)	2005-11-14	2012-03-14	阿里亚德医药股份有限公司	对癌症病人给药mTOR抑制剂
JP2010509400A (ja) *	2006-11-14	2010-03-25	アリアド・ファーマシューティカルズ・インコーポレイテッド	経口処方組成物
US20080175887A1 (en)	2006-11-20	2008-07-24	Lixiao Wang	Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8425459B2 (en)	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414525B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414910B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414526B2 (en) *	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8430055B2 (en) *	2008-08-29	2013-04-30	Lutonix, Inc.	Methods and apparatuses for coating balloon catheters
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8998846B2 (en)	2006-11-20	2015-04-07	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
PE20081891A1 (es) *	2007-03-22	2008-12-27	Opko Health Inc	Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
TW200901989A (en)	2007-04-10	2009-01-16	Wyeth Corp	Anti-tumor activity of CCI-779 in papillary renal cell cancer
JP2008305262A (ja) *	2007-06-08	2008-12-18	Konica Minolta Business Technologies Inc	サーバ及びシンクライアント環境でのプリンタ紹介方法
WO2009089549A1 (en)	2008-01-11	2009-07-16	Massachusetts Eye & Ear Infirmary	Conditional-stop dimerizable caspase transgenic animals
AU2009207796B2 (en)	2008-01-25	2014-03-27	Grunenthal Gmbh	Pharmaceutical dosage form
KR101690094B1 (ko)	2008-05-09	2016-12-27	그뤼넨탈 게엠베하	분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
MX2011000636A (es) *	2008-07-18	2011-08-03	Valeant Pharmaceuticals Int	Formulacion de liberacion modificada y metodos de uso.
CA2765971C (en)	2009-07-22	2017-08-22	Gruenenthal Gmbh	Hot-melt extruded controlled release dosage form
ES2428938T3 (es) *	2009-07-22	2013-11-12	Grünenthal GmbH	Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
WO2011095314A2 (en)	2010-02-03	2011-08-11	Grünenthal GmbH	Preparation of a powdery pharmaceutical composition by means of an extruder
AU2011260016B2 (en)	2010-06-02	2013-08-22	Fresenius Kabi Oncology Ltd.	Stable pharmaceutical compositions of Rapamycin esters
PL2611425T3 (pl)	2010-09-02	2014-09-30	Gruenenthal Gmbh	Odporna na ingerencję postać dawki zawierająca polimer anionowy
RU2604676C2 (ru)	2010-09-02	2016-12-10	Грюненталь Гмбх	Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
US20120303115A1 (en) *	2011-05-25	2012-11-29	Dadino Ronald C	Expandable devices coated with a rapamycin composition
HRP20171458T1 (hr)	2011-07-29	2017-11-17	Grünenthal GmbH	Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
PL2736495T3 (pl)	2011-07-29	2018-01-31	Gruenenthal Gmbh	Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
WO2013127831A1 (en)	2012-02-28	2013-09-06	Grünenthal GmbH	Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
LT2838512T (lt)	2012-04-18	2018-11-12	GrĆ¼nenthal GmbH	Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en)	2012-05-11	2018-09-04	Gruenenthal Gmbh	Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AR096438A1 (es)	2013-05-29	2015-12-30	Gruenenthal Gmbh	Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
JP6445537B2 (ja)	2013-05-29	2018-12-26	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	１個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
US10624862B2 (en)	2013-07-12	2020-04-21	Grünenthal GmbH	Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
US10682415B2 (en)	2013-07-22	2020-06-16	Wisconsin Alumni Research Foundation	Thermogel formulation for combination drug delivery
JP6480936B2 (ja)	2013-11-26	2019-03-13	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	クライオミリングによる粉末状医薬組成物の調製
JP2017518980A (ja)	2014-05-12	2017-07-13	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	タペンタドールを含む、改変防止即時放出カプセル製剤
CN106456550A (zh)	2014-05-26	2017-02-22	格吕伦塔尔有限公司	避免乙醇剂量倾泻的多颗粒
KR20170139158A (ko)	2015-04-24	2017-12-18	그뤼넨탈 게엠베하	즉시 방출되고 용매 추출 방지된 변조 방지된 투여 형태
WO2017038925A1 (ja) *	2015-09-03	2017-03-09	日本化薬株式会社	ラパマイシン又はその誘導体を含有する医薬組成物
WO2017042325A1 (en)	2015-09-10	2017-03-16	Grünenthal GmbH	Protecting oral overdose with abuse deterrent immediate release formulations
WO2017129772A1 (en)	2016-01-29	2017-08-03	Xellia Phamaceuticals Aps	Stable pharmaceutical compositions of temsirolimus

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en) *	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US3993749A (en) *	1974-04-12	1976-11-23	Ayerst Mckenna And Harrison Ltd.	Rapamycin and process of preparation
US4885171A (en) *	1978-11-03	1989-12-05	American Home Products Corporation	Use of rapamycin in treatment of certain tumors
US5206018A (en) *	1978-11-03	1993-04-27	Ayerst, Mckenna & Harrison, Inc.	Use of rapamycin in treatment of tumors
US4401653A (en) *	1981-03-09	1983-08-30	Ayerst, Mckenna & Harrison Inc.	Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) *	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5080899A (en) *	1991-02-22	1992-01-14	American Home Products Corporation	Method of treating pulmonary inflammation
US5078999A (en) *	1991-02-22	1992-01-07	American Home Products Corporation	Method of treating systemic lupus erythematosus
US5321009A (en) *	1991-04-03	1994-06-14	American Home Products Corporation	Method of treating diabetes
ZA924953B (en) *	1991-07-25	1993-04-28	Univ Louisville Res Found	Method of treating ocular inflammation
US5286731A (en) *	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory bowel disease
US5286730A (en) *	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory disease
US5516781A (en) *	1992-01-09	1996-05-14	American Home Products Corporation	Method of treating restenosis with rapamycin
US5288711A (en) *	1992-04-28	1994-02-22	American Home Products Corporation	Method of treating hyperproliferative vascular disease
US5536729A (en) *	1993-09-30	1996-07-16	American Home Products Corporation	Rapamycin formulations for oral administration
IL111004A (en) *	1993-09-30	1998-06-15	American Home Prod	Oral formulations of rapamycin
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
TW403748B (en) *	1994-11-02	2000-09-01	Takeda Chemical Industries Ltd	An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5561138A (en) *	1994-12-13	1996-10-01	American Home Products Corporation	Method of treating anemia
US5496832A (en) *	1995-03-09	1996-03-05	American Home Products Corporation	Method of treating cardiac inflammatory disease
US5705190A (en) *	1995-12-19	1998-01-06	Abbott Laboratories	Controlled release formulation for poorly soluble basic drugs
US5989591A (en) *	1997-03-14	1999-11-23	American Home Products Corporation	Rapamycin formulations for oral administration
CA2230748C (en) *	1997-03-14	2010-08-03	American Home Products Corporation	Rapamycin formulations for oral administration
US5985325A (en) *	1997-06-13	1999-11-16	American Home Products Corporation	Rapamycin formulations for oral administration
US6277983B1 (en) *	2000-09-27	2001-08-21	American Home Products Corporation	Regioselective synthesis of rapamycin derivatives
US20020013335A1 (en) *	2000-06-16	2002-01-31	American Home Products Corporation	Method of treating cardiovascular disease
TWI286074B (en) *	2000-11-15	2007-09-01	Wyeth Corp	Pharmaceutical composition containing CCI-779 as an antineoplastic agent
GB0123400D0 (en) *	2001-09-28	2001-11-21	Novartis Ag	Organic compounds
KR101131794B1 (ko) *	2002-07-30	2012-03-30	와이어쓰 엘엘씨	Ｃｃｉ-779 공용매 농축액, 비경구 ｃｃｉ-779 제형 및 비경구 ｃｃｉ-779 제형의 제조방법

2003
- 2003-09-15 JP JP2004537911A patent/JP2006506353A/ja active Pending
- 2003-09-15 MX MXPA05002828A patent/MXPA05002828A/es active IP Right Grant
- 2003-09-15 DK DK03754672T patent/DK1635830T3/da active
- 2003-09-15 KR KR1020057004555A patent/KR20050084559A/ko not_active Ceased
- 2003-09-15 WO PCT/US2003/029228 patent/WO2004026280A2/en not_active Ceased
- 2003-09-15 US US10/663,506 patent/US20040077677A1/en not_active Abandoned
- 2003-09-15 AU AU2003272489A patent/AU2003272489B2/en not_active Ceased
- 2003-09-15 SI SI200331456T patent/SI1635830T1/sl unknown
- 2003-09-15 PT PT03754672T patent/PT1635830E/pt unknown
- 2003-09-15 DE DE60324609T patent/DE60324609D1/de not_active Expired - Lifetime
- 2003-09-15 BR BR0314397-0A patent/BR0314397A/pt not_active IP Right Cessation
- 2003-09-15 UA UAA200503586A patent/UA81265C2/uk unknown
- 2003-09-15 AT AT03754672T patent/ATE413163T1/de not_active IP Right Cessation
- 2003-09-15 CN CNB03822013XA patent/CN100415233C/zh not_active Expired - Fee Related
- 2003-09-15 CA CA002496332A patent/CA2496332A1/en not_active Abandoned
- 2003-09-15 ES ES03754672T patent/ES2315530T3/es not_active Expired - Lifetime
- 2003-09-15 EP EP03754672A patent/EP1635830B1/en not_active Expired - Lifetime
- 2003-09-15 NZ NZ538781A patent/NZ538781A/en unknown
- 2003-09-15 RU RU2005111222/15A patent/RU2326654C2/ru not_active IP Right Cessation
2005
- 2005-02-10 IL IL16682405A patent/IL166824A0/xx unknown
- 2005-02-16 NO NO20050836A patent/NO20050836L/no not_active Application Discontinuation
- 2005-03-16 ZA ZA200502220A patent/ZA200502220B/en unknown
- 2005-04-08 CR CR7791A patent/CR7791A/es not_active Application Discontinuation
- 2005-04-13 EC EC2005005731A patent/ECSP055731A/es unknown

Also Published As

Publication number	Publication date
WO2004026280A3 (en)	2005-12-01
HK1084050A1 (en)	2006-07-21
NO20050836L (no)	2005-04-15
ES2315530T3 (es)	2009-04-01
RU2005111222A (ru)	2005-09-20
NZ538781A (en)	2007-11-30
IL166824A0 (en)	2006-01-15
PT1635830E (pt)	2008-12-31
BR0314397A (pt)	2005-08-09
ATE413163T1 (de)	2008-11-15
RU2326654C2 (ru)	2008-06-20
WO2004026280A2 (en)	2004-04-01
EP1635830B1 (en)	2008-11-05
DK1635830T3 (da)	2009-02-23
EP1635830A2 (en)	2006-03-22
ZA200502220B (en)	2008-01-30
US20040077677A1 (en)	2004-04-22
CA2496332A1 (en)	2004-04-01
KR20050084559A (ko)	2005-08-26
DE60324609D1 (de)	2008-12-18
AU2003272489B2 (en)	2008-11-13
AU2003272489A1 (en)	2004-04-08
ECSP055731A (es)	2005-07-06
MXPA05002828A (es)	2005-05-27
CN100415233C (zh)	2008-09-03
CN1764459A (zh)	2006-04-26
UA81265C2 (en)	2007-12-25
JP2006506353A (ja)	2006-02-23
CR7791A (es)	2007-10-01

Publication	Publication Date	Title
PT1635830E (pt)	2008-12-31	Formulação granulada do éster de rapamicina cci-779
NO20050455L (no)	2005-02-09	Parenterale formuleringer inneholdende en rapamycinhydroksyester
SG145716A1 (en)	2008-09-29	Amorphous rapamycin 42-ester with 3-hydroxy-2- (hydroxymethyl)-2- methylpropionic acid and pharmaceutical compositions containing the same
AR031341A1 (es)	2003-09-17	Uso de cci-779 como agente antineoplastico
AU2003288970A1 (en)	2004-06-07	Fabric treatment compositions comprising oppositely charged polymers
AU2002351647A1 (en)	2003-06-10	Kit for implanting an intra-ocular lens
MXPA06007829A (es)	2006-09-01	Composicion farmaceutica directamente comprimible para la administracion oral de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico.
NO20040775L (no)	2004-02-17	Oftalmisk sammensetning som innbefatter et askomycin
IL172573A0 (en)	2006-04-10	Cci-779 lyophilized formulations
CL2007002988A1 (es)	2008-01-18	Proceso para la preparacion de un isomero individual de rapamicina 42 ester con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico (cci-779) monopegilado.
WO2004087073A3 (en)	2005-11-03	Treatment of demyelinating conditions
BRPI0518079A (pt)	2008-11-04	usos de um inibidor de mtor, de uma rapamicina, e de 42-éster de rapamicina com ácido 3-hidróxi-2- (hidroximetil) -2-metilpropiÈnico, composição farmacêutica, e, embalagem farmacêutica
AU2002308301A1 (en)	2003-09-09	Malodor counteracting composition
BRPI0408423A (pt)	2006-03-21	composições farmacêuticas compreendendo uma combinação de rapamicina ou seus derivados e pimecrolimus para o tratamento de doenças mediadas imunologicamente e por inflamação
AU2003290127A1 (en)	2005-07-21	4-amino-7,8-dihydropteridines, pharmaceutical compositions containing them and their use for the treatment of diseases which are caused by an increased nitric oxide level
AU2003283252A1 (en)	2004-04-19	Lingual retainer
WO2007056175A3 (en)	2007-06-28	41-methoxy isotope labeled rapamycin 42-ester
AU2003225483A1 (en)	2003-10-20	Machinery for automatic x-ray inspection of wheels
AU2003213107A1 (en)	2003-09-09	Methods for analysis of molecular events
UA83697C2 (ru)	2008-08-11	Cci-779 для лечения лимфомы из мантийных клеток
HK1085935A (en)	2006-09-08	Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same
AU2003235722A1 (en)	2003-07-30	Polymeric compositions
HK1084597A (en)	2006-08-04	Cci-779 lyophilized formulations
HK1071509A (en)	2005-07-22	Use of an ascomycin for the treatment of blepharitis
HK1078759A (en)	2006-03-24	Polysilsesquioxane containing polymeric compositions